Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms (original) (raw)

• Dalton WS . Mechanisms of drug resistance in hematologic malignancies. Semin Hematol 1997; 34: 3–8.
  CAS PubMed Google Scholar
• Sonneveld P, Lokhorst HM, Vossebeld P . Drug resistance in multiple myeloma. Semin Hematol 1997; 34(Suppl 5): 34–39.
  CAS PubMed Google Scholar
• Shain KH, Dalton WS . Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 2001; 1: 69–78.
  CAS PubMed Google Scholar
• Damiano JS, Dalton WS . Integrin-mediated drug resistance in multiple myeloma. Leukemia and Lymphoma 2000; 38: 71–81.
  Article CAS PubMed Google Scholar
• Shain KH, Landowski TH, Dalton WS . The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol 2000; 12: 557–563.
  Article CAS PubMed Google Scholar
• Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5: 662–667.
  Article CAS PubMed Google Scholar
• Garrido SM, Appelbaum FR, Willman CL, Banker DE . Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001; 29: 448–457.
  Article CAS PubMed Google Scholar
• Mudry RE, Fortney JE, York T, Hall BM, Gibson LF . Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000; 96: 1926–1932.
  CAS PubMed Google Scholar
• Cheung WC, Van Ness B . The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia 2001; 15: 264–271.
  Article CAS PubMed Google Scholar
• Nachbaur DM, Herold M, Maneschg A, Huber H . Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 1991; 62: 54–58.
  Article CAS PubMed Google Scholar
• Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000; 85: 800–805.
  CAS PubMed Google Scholar
• Bataille R, Jourdan M, Zhang XG, Klein B . Serum levels of interleukin 6, a potent myeloma cell growth factor as a reflect, of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008–2011.
  Article CAS PubMed PubMed Central Google Scholar
• Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064–3073.
  CAS PubMed Google Scholar
• Zhang XG, Bataille R, Widjenes J, Klein B . Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer 1992; 69: 1373–1376.
  Article CAS PubMed Google Scholar
• Ruoslahti E, Reed JC . Anchorage dependence integrins and apoptosis. Cell 2000; 77: 477–478.
  Article Google Scholar
• Scott G, Cassidy L, Busacco A . Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism. J Invest Dermatol 1997; 108: 147–153.
  Article CAS PubMed Google Scholar
• de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, Garcia-Marco J et al. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukocyte Biol 2002; 71: 495–502.
  CAS PubMed Google Scholar
• Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS . Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658–1667.
  CAS PubMed Google Scholar
• Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS . Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19: 4319–4327.
  Article CAS PubMed Google Scholar
• Shain KH, Landowski TH, Dalton WS . Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002; 168: 2544–2553.
  Article CAS PubMed Google Scholar
• Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P . Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91: 2387–2396.
  CAS PubMed Google Scholar
• Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630–2636.
  CAS PubMed Google Scholar
• Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R et al. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res 2001; 7: 4262–4271.
  CAS PubMed Google Scholar
• Damiano JS, Hazlehurst LA, Dalton WS . Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 2001; 15: 1232–1239.
  Article CAS PubMed Google Scholar
• Dalton WS, Cress AE, Alberts DS, Trent JM . Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 1988; 48: 1882–1888.
  CAS PubMed Google Scholar
• Durie BGM, Dalton WS . Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988; 68: 203–206.
  Article CAS PubMed Google Scholar
• Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 1999; 59: 1021–1028.
  CAS PubMed Google Scholar
• Sezer O, Jakob C, Eucker J, Niemoller K, Gatz F, Wernecke K et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001; 66: 83–88.
  Article CAS PubMed Google Scholar
• Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 2002; 277: 7875–7881.
  Article CAS PubMed Google Scholar
• Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC . Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712–3720.
  CAS PubMed Google Scholar
• Faid L, Van RI, De Waele M, Facon T, Schots R et al. Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma. Eur J Haematol 1996; 57: 349–358.
  Article CAS PubMed Google Scholar
• Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990; 247: 1457–1461.
  Article CAS PubMed Google Scholar
• Green SK, Frankel A, Kerbel RS . Adhesion-dependent multi-cellular drug resistance. Anticancer Drug Des 1999; 14: 153–168.
  CAS PubMed Google Scholar
• Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM et al. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001; 98: 1897–1903.
  Article CAS PubMed Google Scholar
• Sanz-Rodriguez F, Ruiz-Velasco N, Pascual-Salcedo D, Teixido J . Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br J Haematol 1999; 107: 825–834.
  Article CAS PubMed Google Scholar
• Bellamy WT, Richter L, Frutiger Y, Grogan TM . Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728–733.
  CAS PubMed Google Scholar
• Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428–435.
  Article CAS PubMed Google Scholar